Kymera Therapeutics (KYMR) shares were down 7.6% in Monday trading after RBC downgraded the stock to sector perform from outperform and raised its price target to $115 from $106 with speculative risk.
Intraday trading volume stood at about 533,000 shares against a daily average of over 790,000 shares.
Price: $110.31, Change: $-9.04, Percent Change: -7.58%